Haemophilus influenzae type b disease in the era of conjugate vaccines: critical factors for successful eradication

References

• World Health Organization. Haemophilus influenzae type b (Hib) vaccination position paper - July 2013. Wkly Epidemiol Rec. 2013;88(39):413–426.
   PubMedGoogle Scholar
• World Health Organization. Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates. 2002. [ cited 2019 Nov 18]. Available from: http://apps.who.int/iris/bitstream/handle/10665/67572/WHO_V-B_02.18_eng.pdf.
   Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, et al., Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 6(7): e744–e757. 2018. .
   PubMed Web of Science ®Google Scholar
• Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: A systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317–328. .
   PubMed Web of Science ®Google Scholar
• Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev. 2007;20(2):368–389.
   PubMed Web of Science ®Google Scholar
• Van Eldere J, Slack MP, Ladhani S, et al. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis. 2014;14(12):1281–1292. .
   PubMed Web of Science ®Google Scholar
• Su PY, Huang AH, Lai CH, et al. Extensively drug-resistant Haemophilus influenzae - emergence, epidemiology, risk factors, and regimen. BMC Microbiol. 2020;20(1):102.
   PubMed Web of Science ®Google Scholar
• Kayhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147(6):1100.
   PubMed Web of Science ®Google Scholar
• Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1984;149(6):1034–1035.
   PubMed Web of Science ®Google Scholar
• Fernandez J, Levine OS, Sanchez J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis. 2000;182(5):1553–1556.
   PubMed Web of Science ®Google Scholar
• Zarei AE, Almehdar HA, Redwan EM. Hib vaccines: past, present, and future perspectives. J Immunol Res. 2016;2016:7203587.
   PubMed Web of Science ®Google Scholar
• Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13(2):302–317.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunological basis for immunization: haemophilus influenzae type b vaccines. 2007. [ cited 2019 Nov 18]. Available from: http://apps.who.int/iris/handle/10665/43799.
   Google Scholar
• World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary. 2019. [ cited 2020 Jan 17]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules.
   Google Scholar
• World Health Organization. Immunization coverage. Key facts. 2019. [ cited 2019 Jul 20]. Available from: http://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
   Google Scholar
• European Centre for Disease Prevention and Control. ECDC. Annual epidemiological report for 2017. In: Haemophilus influenzae. Stockholm: ECDC; 2019.
   Google Scholar
• Bajanca-Lavado MP, Bettencourt C, Cunha F, et al. Haemophilus influenzae serotype b vaccine failure in Portugal: A new threat? OC- EMGM2019-13331. 15th EMGM Congress, 27-30 May 2019; Lisbon, Portugal.
   Google Scholar
• Hong E, Terrade A, Denizon M, et al. Recent evolution of the epidemiology of Haemophilus influenzae type b and seroprevalence in France. OC EMGM2019-13190. 15th EMGM Congress, 27-30 May 2019; Lisbon, Portugal.
   Google Scholar
• WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec. WHO; 2006;81(47):445–452.
   PubMedGoogle Scholar
• Progress introducing Haemophilus influenzae type b vaccine in low-income countries, 2004-2008. Wkly Epidemiol Rec. 2008;83(7):61–67.
   Google Scholar
• Sambala EZ, Wiyeh AB, Ngcobo N, et al. New vaccine introductions in Africa before and during the decade of vaccines - Are we making progress? Vaccine. 2019;37(25):3290–3295.
   PubMed Web of Science ®Google Scholar
• Nanduri SA, Sutherland AR, Gordon LK, et al. Haemophilus influenzae type b vaccines. In: Plotkin’s Vaccines. Elsevier; 2018. p. 301–318. e310.
   Google Scholar
• Walls T, Cho V, Martin N, et al., Vaccine impact on long-term trends in invasive bacterial disease in New Zealand children. Pediatr Infect Dis J. 37(10): 1041–1047. 2018. .
   PubMed Web of Science ®Google Scholar
• Martinelli D, Azzari C, Bonanni P, et al. Impact of Haemophilus influenzae type b conjugate vaccination on hospitalization for invasive disease in children fifteen years after its introduction in Italy. Vaccine. 2017;35(46):6297–6301. .
   PubMed Web of Science ®Google Scholar
• Soeters HM, Blain A, Pondo T, et al., Current epidemiology and trends in invasive Haemophilus influenzae disease-United States, 2009-2015. Clin Infect Dis. 67(6): 881–889. 2018. .
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report. Emerging Infections Program Network. In: Haemophilus influenza. 2017. 2019 Aug 1 cited]. Available from http://www.cdc.gov/abcs/reports-findings/survreports/hib17.html
   Google Scholar
• Wang S, Tafalla M, Hanssens L, et al. A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines. 2017;16(11):1095–1105. .
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. Invasive Haemophilus influenzae disease. Serotype b reported cases. 2019. [ cited 2020 Jan 17]. Available from: http://atlas.ecdc.europa.eu/public/index.aspx.
   Google Scholar
• Dey A, Knox S, Wang H, et al. Summary of national surveillance data on vaccine preventable diseases in Australia, 2008-2011. Commun Dis Intell Q Rep. 2016;40(Suppl):S1–70.
   PubMedGoogle Scholar
• Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005;366(9480):144–150. .
   PubMed Web of Science ®Google Scholar
• Howie SR, Oluwalana C, Secka O, et al. The effectiveness of conjugate Haemophilus influenzae type B vaccine in The Gambia 14 years after introduction. Clin Infect Dis. 2013;57(11):1527–1534. .
   PubMed Web of Science ®Google Scholar
• Oluwalana C, Howie SR, Secka O, et al. Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. J Pediatr. 2013;163(1 Suppl):S4–7. .
   PubMed Web of Science ®Google Scholar
• Zaman SM, Howie SR, Ochoge M, et al. Impact of routine vaccination against Haemophilus influenzae type b in The Gambia: 20 years after its introduction. J Glob Health. 2020;10(1):010416. .
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Crane RJ, Karani A, et al. Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study. Lancet Glob Health. 2016;4(3):e185–194. .
   PubMed Web of Science ®Google Scholar
• Wall EC, Everett DB, Mukaka M, et al. Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and Haemophilus influenzae type b vaccination, 2000-2012. Clin Infect Dis. 2014;58(10):e137–145.
   PubMed Web of Science ®Google Scholar
• Suga S, Ishiwada N, Sasaki Y, et al., A nationwide population-based surveillance of invasive Haemophilus influenzae diseases in children after the introduction of the Haemophilus influenzae type b vaccine in Japan. Vaccine. 36(38): 5678–5684. 2018. .
   PubMed Web of Science ®Google Scholar
• Thoon KC, Tee NW, Chew L, et al. Near disappearance of childhood invasive Haemophilus influenzae type b disease in Singapore. Vaccine. 2014;32(44):5862–5865.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Reported estimates of Hib3 coverage. Last updated 10 December 2019. [ cited 2020 Jan 14]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragehib3.html.
   Google Scholar
• Blain A, MacNeil J, Wang X, et al. Invasive Haemophilus influenzae disease in adults ≥65 years, United States, 2011. Open Forum Infect Dis. 2014;1(2):ofu044.
   PubMedGoogle Scholar
• Cox AD, Barreto L, Ulanova M, et al. Developing a vaccine for Haemophilus influenzae serotype a: proceedings of a workshop. Can Commun Dis Rep. 2017;43(5):89–95.
   PubMedGoogle Scholar
• Whittaker R, Economopoulou A, Dias JG, et al. Epidemiology of invasive Haemophilus influenzae disease, Europe, 2007-2014. Emerg Infect Dis. 2017;23(3):396–404.
   PubMed Web of Science ®Google Scholar
• Adam HJ, Richardson SE, Jamieson FB, et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine. 2010;28(24):4073–4078.
   PubMed Web of Science ®Google Scholar
• Ribeiro GS, Reis JN, Cordeiro SM, et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis. 2003;187(1):109–116.
   PubMed Web of Science ®Google Scholar
• Ladhani S, Ramsay ME, Chandra M, et al. No evidence for Haemophilus influenzae serotype replacement in Europe after introduction of the Hib conjugate vaccine. Lancet Infect Dis. 2008;8(5):275–276.
   PubMed Web of Science ®Google Scholar
• Ladhani S, Slack MP, Heath PT, et al. Invasive Haemophilus influenzae disease, Europe, 1996-2006. Emerg Infect Dis. 2010;16(3):455–463.
   PubMed Web of Science ®Google Scholar
• Gentile A, Martinez AC, Juarez MDV, et al. Haemophilus influenzae type B meningitis: is there a re-emergence? 24 years of experience in a children’s hospital. Arch Argent Pediatr. 2017;115(3):227–233.
   PubMed Web of Science ®Google Scholar
• Shah RK, Roberson DW, Jones DT. Epiglottitis in the Hemophilus influenzae type b vaccine era: changing trends. Laryngoscope. 2004;114(3):557–560.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. ECDC. Annual epidemiological report for 2016. In: Haemophilus influenzae. Stockholm: ECDC; 2018.
   Google Scholar
• Garcia S, Ciriaci C, Montes G, et al. [Epiglottitis due to Haemophilus influenzae type b in the vaccination era: pediatric clinical case]. Arch Argent Pediatr. 2019;117(4):e403–e405.
   PubMed Web of Science ®Google Scholar
• Heath PT. Haemophilus influenzae type b conjugate vaccines: A review of efficacy data. Pediatr Infect Dis J. 1998;17(9 Suppl):S117–122.
   PubMed Web of Science ®Google Scholar
• Mulholland EK, Adegbola RA, Gambian T. Haemophilus influenzae type b vaccine trial: what does it tell us about the burden of Haemophilus influenzae type b disease? Pediatr Infect Dis J. 1998;17(9 Suppl):S123–125.
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 1999;354(9195):2063–2068. .
   PubMed Web of Science ®Google Scholar
• Kalies H, Verstraeten T, Grote V, et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J. 2004;23(10):944–950.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO prequalified vaccines (last updated June 2020). [ cited 2020 Jun 12]. Available from: https://extranet.who.int/gavi/PQ_Web/Default.aspx?nav=2.
   Google Scholar
• Bulkow LR, Wainwright RB, Letson GW, et al. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J. 1993;12(6):484–492.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr. 1992;121(2):187–194.
   PubMed Web of Science ®Google Scholar
• Wetzler LM. Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity. Future Microbiol. 2010;5(5):749–758.
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM, Bradley R, et al. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr. 1992;120(2 Pt 1):184–189.
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Iwarson S, et al. Antibodies against Haemophilus influenzae type b and tetanus in infants after subcutaneous vaccination with PRP-T/diphtheria, or PRP-OMP/diphtheria-tetanus vaccines. Pediatr Infect Dis J. 1994;13(1):27–33.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Becker T, Vertruyen AF, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at two, three, four and twelve months. Pediatr Infect Dis J. 2017;36(2):209–215.
   PubMed Web of Science ®Google Scholar
• Silfverdal SA, Icardi G, Vesikari T, et al. A phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months. Vaccine. 2016;34(33):3810–3816.
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson B A, Lagergard T, et al. Serum antibodies against Haemophilus influenzae type b and tetanus at 2.5 years of age: A follow-up of 2 different regimens of infant vaccination. Scand J Infect. 1996;28(5):519–523.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Lopez P, Zambrano B, et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2019;15(3):658–668.
   PubMed Web of Science ®Google Scholar
• Zinke M, Disselhoff J, Gartner B, et al. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin. 2010;6(2):189–193.
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The vaccine study group. JAMA. 1992;267(11):1489–1494.
   PubMed Web of Science ®Google Scholar
• Agbarakwe AE, Griffiths H, Begg N, et al. Avidity of specific IgG antibodies elicited by immunisation against Haemophilus influenzae type b. J Clin Pathol. 1995;48(3):206–209.
   PubMed Web of Science ®Google Scholar
• Low N, Redmond SM, Rutjes AW, et al. Comparing Haemophilus influenzae type b conjugate vaccine schedules: a systematic review and meta-analysis of vaccine trials. Pediatr Infect Dis J. 2013;32(11):1245–1256.
   PubMed Web of Science ®Google Scholar
• Thumburu KK, Singh M, Das RR, et al. Two or three primary dose regime for Haemophilus influenzae type b conjugate vaccine: meta-analysis of randomized controlled trials. Ther Adv Vaccines. 2015;3(2):31–40.
   PubMedGoogle Scholar
• Watt J, Chen S, Santosham M Haemophilus influenzae type b conjugate vaccine: review of observational data on long term vaccine impact to inform recommendations for vaccine schedules, Geneva, World Health Organization. 2012. [ cited 2020 Feb 25]. Available from: http://www.who.int/immunization/sage/meetings/2012/november/5_Review_observational_data_long_term_vaccine_impact_recommendations_vaccine_schedules_Watt_J_et_al_2012.pdf.
   Google Scholar
• Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000;284(18):2334–2340.
   PubMed Web of Science ®Google Scholar
• Ladhani S, Slack MP, Heys M, et al. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child. 2008;93(8):665–669.
   PubMed Web of Science ®Google Scholar
• Collins S, Litt D, Almond R, et al. Haemophilus influenzae type b (Hib) seroprevalence and current epidemiology in England and Wales. J Infect. 2018;76(4):335–341.
   PubMed Web of Science ®Google Scholar
• Public Health England. Laboratory reports of Haemophilus influenzae type b infection by age group and quarter: england, 1990-2014. In: Haemophilus influenzae: epidemiological data. 2015. 2020 Jan 17 cited]. Available from http://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/407091/Laboratory_reports_of_Haemophilus_influenzae_type_b_infection_by_age_group_and_quarter_England_1990_-_2014.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Haemophilus Influenzae type B infection: recommended vaccinations. [ cited 2020 Jul 29]. Available from: http://vaccine-schedule.ecdc.europa.eu/.
   Google Scholar
• Charania NA, Moghadas SM. Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b. BMC Public Health. 2017;17(1):705.
   PubMedGoogle Scholar
• Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther. 2012;34(2):385–399. .
   PubMed Web of Science ®Google Scholar
• Borrow R, Dagan R, Zepp F, et al. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines. 2011;10(11):1621–1631.
   PubMed Web of Science ®Google Scholar
• Voysey M, Sadarangani M, Clutterbuck E, et al. The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: a systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34(34):3986–3992.
   PubMed Web of Science ®Google Scholar
• Moro PL, Jankosky C, Menschik D, et al. Adverse events following Haemophilus influenzae type b vaccines in the vaccine adverse event reporting system, 1990-2013. J Pediatr. 2015;166(4):992–997.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Daum RS. Spread of Haemophilus influenzae type b: recent epidemiologic and therapeutic considerations. J Pediatr. 1980;97(5):854–860.
   PubMed Web of Science ®Google Scholar
• Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis. 2008;8(7):435–443.
   PubMed Web of Science ®Google Scholar
• de Carvalho CX, Kipnis A, Thörn L, et al. Carriage of Haemophilus influenzae among Brazilian children attending day care centers in the era of widespread Hib vaccination. Vaccine. 2011;29(7):1438–1442. .
   PubMed Web of Science ®Google Scholar
• McVernon J, Howard AJ, Slack MP, et al. Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect. 2004;132(4):765–767.
   PubMed Web of Science ®Google Scholar
• DeAntonio R, Amador S, Bunge EM, et al. Vaccination herd effect experience in Latin America: a systematic literature review. Hum Vaccin Immunother. 2019;15(1):49–71.
   PubMed Web of Science ®Google Scholar
• McVernon J, Trotter CL, Slack MP, et al. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ. 2004;329(7467):655–658.
   PubMedGoogle Scholar
• Michaels RH, Norden CW. Pharyngeal colonization with Haemophilus influenzae type b: a longitudinal study of families with a child with meningitis or epiglottitis due to H. influenzae type b. J Infect Dis. 1977;136(2):222–228.
   PubMed Web of Science ®Google Scholar
• Giufre M, Daprai L, Cardines R, et al. Carriage of Haemophilus influenzae in the oropharynx of young children and molecular epidemiology of the isolates after fifteen years of H. influenzae type b vaccination in Italy. Vaccine. 2015;33(46):6227–6234.
   PubMed Web of Science ®Google Scholar
• Zanella RC, Brandileone MC, Andrade AL, et al. Evaluation of Haemophilus influenzae type b carrier status among children 10 years after the introduction of Hib vaccine in Brazil. Mem Inst Oswaldo Cruz. 2015;110(6):755–759. .
   PubMed Web of Science ®Google Scholar
• Singleton R, Hammitt L, Hennessy T, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics. 2006;118(2):e421–429.
   PubMed Web of Science ®Google Scholar
• Menzies RI, Bremner KM, Wang H, et al. Long-term trends in invasive Haemophilus influenzae type b disease among indigenous Australian children following use of PRP-OMP and PRP-T vaccines. Pediatr Infect Dis J. 2015;34(6):621–626.
   PubMed Web of Science ®Google Scholar
• Tsang RS, Bruce MG, Lem M, et al., A review of invasive Haemophilus influenzae disease in the Indigenous populations of North America. Epidemiol Infect. 142(7): 1344–1354. 2014. .
   PubMed Web of Science ®Google Scholar
• Jacups SP, Morris PS, Leach AJ. Haemophilus influenzae type b carriage in Indigenous children and children attending childcare centers in the Northern Territory, Australia, spanning pre- and post-vaccine eras. Vaccine. 2011;29(16):3083–3088.
   PubMed Web of Science ®Google Scholar
• Cleland G, Leung C, Wan Sai Cheong J, et al. Paediatric invasive Haemophilus influenzae in Queensland, Australia, 2002-2011: young Indigenous children remain at highest risk. J Paediatr Child Health. 2018;54(1):36–41.
   PubMed Web of Science ®Google Scholar
• Diseases AAoPCoI. Red book: report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
   Google Scholar
• Briere EC, Rubin L, Moro PL, et al. Prevention and control of Haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014;63(RR–01):1–14.
   PubMedGoogle Scholar
• Kristensen K. Antibody response to a Haemophilus influenzae type b polysaccharide tetanus toxoid conjugate vaccine in splenectomized children and adolescents. Scand J Infect Dis. 1992;24(5):629–632.
   PubMed Web of Science ®Google Scholar
• Meerveld-Eggink A, de Weerdt O, van Velzen-blad H, et al. Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients. Vaccine. 2011;29(4):675–680.
   PubMed Web of Science ®Google Scholar
• Feldman S, Gigliotti F, Shenep JL, et al. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis. 1990;161(5):926–931. .
   PubMed Web of Science ®Google Scholar
• Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type b in patients with multiple myeloma. Br J Cancer. 2000;82(7):1261–1265. .
   PubMed Web of Science ®Google Scholar
• Mangtani P, Mulholland K, Madhi SA, et al. Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine. 2010;28(7):1677–1683. .
   PubMed Web of Science ®Google Scholar
• Baxter D. Vaccine responsiveness in premature infants. Hum Vaccin. 2010;6(6):506–511.
   PubMed Web of Science ®Google Scholar
• Heath PT, Booy R, McVernon J, et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003;88(3):206–210. .
   PubMed Web of Science ®Google Scholar
• Bednarek A, Bartkowiak-Emeryk M, Klepacz R, et al. Persistence of vaccine-induced immunity in preschool children: effect of gestational age. Med Sci Monit. 2018;24:5110–5117.
   PubMed Web of Science ®Google Scholar
• Omenaca F, Garcia-Sicilia J, Boceta R, et al. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J. 2007;26(9):824–829. 10.4161/hv.6.2.10117.
   PubMed Web of Science ®Google Scholar
• Omenaca F, Vazquez L, Garcia-Corbeira P, et al. Immunization of preterm infants with GSK’s hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Vaccine. 2018;36(7):986–996.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang Y, Scherpbier RW, et al. Coverage of Haemophilus influenzae type b conjugate vaccine for children in mainland China: systematic review and meta-analysis. Pediatr Infect Dis J. 2019;38(3):248–252. .
   PubMed Web of Science ®Google Scholar
• Meningitis Research Foundation (MRF). Global plan to defeat meningitis gets go ahead to progress to World Health Assembly. 18 February 2020. [ cited 2020 Jun 12]. Available from: https://www.meningitis.org/meningitis-2030-plan-agreed-by-who.
   Google Scholar
• The Lancet. A new roadmap for meningitis. Lancet. 2020;395(10232):1230.
   Web of Science ®Google Scholar
• Hallander HO, Lepp T, Ljungman M, et al. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS. 2010;118(11):878–887.
   PubMed Web of Science ®Google Scholar
• Barbour ML, Mayon-White RT, Coles C, et al. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis. 1995;171(1):93–98.
   PubMed Web of Science ®Google Scholar
• Forleo-Neto E, de Oliveira CF, Maluf EM, et al. Decreased point prevalence of Haemophilus influenzae type b (Hib) oropharyngeal colonization by mass immunization of Brazilian children less than 5 years old with Hib polyribosylribitol phosphate polysaccharide-tetanus toxoid conjugate vaccine in combination with diphtheria-tetanus toxoids-pertussis vaccine. J Infect Dis. 1999;180(4):1153–1158.
   PubMed Web of Science ®Google Scholar
• Murphy TV, Pastor P, Medley F, et al. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr. 1993;122(4):517–523.
   PubMed Web of Science ®Google Scholar
• Rushdy A, Ramsay M, Heath PT, et al. Infant Hib vaccination and herd immunity. J Pediatr. 1999;134(2):253–254.
   PubMed Web of Science ®Google Scholar
• Gilkey MB, McRee AL, Magnus BE, et al. Vaccination confidence and parental refusal/delay of early childhood vaccines. PLoS One. 2016;11(7):e0159087.
   PubMed Web of Science ®Google Scholar
• McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clin Ther. 2017;39(8):1550–1562.
   PubMed Web of Science ®Google Scholar
• World Health Organization. New measles surveillance data from WHO- Provisional data based on monthly reports to WHO (Geneva) as of August 2019. [ cited 2019 Jul 29]. Available from: http://www.who.int/immunization/newsroom/new-measles-data-august-2019/en/.
   Google Scholar
• Ali M, Ahmad N, Khan H, et al. Polio vaccination controversy in Pakistan. Lancet. 2019;394(10202):915–916.
   PubMed Web of Science ®Google Scholar
• Saitoh A, Aizawa Y. Intradermal vaccination for infants and children. Hum Vaccin Immunother. 2016;12(9):2447–2455.
   PubMed Web of Science ®Google Scholar
• Zehrung D, Jarrahian C, Wales A. Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine. 2013;31(34):3392–3395.
   PubMed Web of Science ®Google Scholar
• Cox AD, Williams D, Cairns C, et al., Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: A solution for an unmet public health need. Vaccine. 35(45): 6129–6136. 2017. .
   PubMed Web of Science ®Google Scholar